- Home
- CLLS vs SFST Comparison
CLLS vs SFST Comparison
Compare CLLS & SFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SFST
- Stock Information
- Founded
- CLLS 1999
- SFST 1999
- Country
- CLLS France
- SFST United States
- Employees
- CLLS N/A
- SFST N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SFST Major Banks
- Sector
- CLLS Health Care
- SFST Finance
- Exchange
- CLLS Nasdaq
- SFST Nasdaq
- Market Cap
- CLLS 240.2M
- SFST N/A
- IPO Year
- CLLS 2007
- SFST 1999
- Fundamental
- Price
- CLLS $1.97
- SFST $33.74
- Analyst Decision
- CLLS Buy
- SFST Buy
- Analyst Count
- CLLS 2
- SFST 1
- Target Price
- CLLS $8.00
- SFST $44.00
- AVG Volume (30 Days)
- CLLS 22.5K
- SFST 20.7K
- Earning Date
- CLLS 11-04-2024
- SFST 10-17-2024
- Dividend Yield
- CLLS N/A
- SFST N/A
- EPS Growth
- CLLS N/A
- SFST N/A
- EPS
- CLLS N/A
- SFST 1.70
- Revenue
- CLLS $19,635,000.00
- SFST $88,995,000.00
- Revenue This Year
- CLLS $271.02
- SFST N/A
- Revenue Next Year
- CLLS $33.48
- SFST $13.55
- P/E Ratio
- CLLS N/A
- SFST $19.78
- Revenue Growth
- CLLS N/A
- SFST N/A
- 52 Week Low
- CLLS $0.96
- SFST $24.98
- 52 Week High
- CLLS $3.77
- SFST $39.36
- Technical
- Relative Strength Index (RSI)
- CLLS 37.13
- SFST 57.51
- Support Level
- CLLS $1.88
- SFST $33.26
- Resistance Level
- CLLS $2.08
- SFST $34.42
- Average True Range (ATR)
- CLLS 0.12
- SFST 0.82
- MACD
- CLLS -0.04
- SFST -0.01
- Stochastic Oscillator
- CLLS 17.31
- SFST 50.57
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.